You just read:

Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA

News provided by

Regeneron Pharmaceuticals, Inc.

Jan 26, 2015, 01:00 ET